Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer

Andrew Rowland,Mafalda M. Dias,Michael D. Wiese,Ganessan Kichenadasse,Ross A. McKinnon,Christos S. Karapetis,Michael J. Sorich

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer

2015

Andrew Rowland
Mafalda M. Dias
Michael D. Wiese
Ganessan Kichenadasse
Ross A. McKinnon
Christos S. Karapetis
Michael J. Sorich

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer

Keywords:

Breast cancer
Immunology
Skin cancer
Pathology
Prostate cancer
Colorectal cancer
Liver cancer
Medicine
Biomarker (medicine)
Monoclonal antibody therapy
Lung cancer
Hazard ratio
Oncogene

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

193

Citations